Short-term prophylactic tamoxifen reduces the incidence of antiestrogen-resistant/estrogen receptor-positive/progesterone receptor-negative mammary tumors

Cancer Prevention Research

Volumn 2, Issue 5, 2009, Pages 496-502

  Rose Hellekant, Teresa A ^a   Skildum, Andrew J ^a   Zhdankin, Olga ^a   Greene, Amy L ^a,c   Regal, Ronald R ^b   Kundel, Katherine D ^a   Kundel, Donald W ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA DULUTH   (United States)

^c MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN RECEPTOR; FULVESTRANT; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA; DRUG DERIVATIVE; ESTRADIOL; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST TUMOR; CANCER INCIDENCE; CANCER THERAPY; CARCINOGENESIS; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL MODEL; GROWTH INHIBITION; LIFESPAN; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THERAPY EFFECT; TRANSGENIC MOUSE; TREATMENT DURATION; TUMOR GROWTH; ANIMAL; BIOSYNTHESIS; DRUG RESISTANCE; EXPERIMENTAL NEOPLASM; FEMALE; GENETICS; IMMUNOHISTOCHEMISTRY; INCIDENCE; METABOLISM;

ANIMALS; DRUG RESISTANCE, NEOPLASM; ESTRADIOL; ESTROGEN RECEPTOR MODULATORS; FEMALE; IMMUNOHISTOCHEMISTRY; INCIDENCE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 67650334402     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0002     Document Type: Article

References (31)

1. Osborne CK. Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998;51:227-238 (Pubitemid 29054556)
2. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21:1973-1979 (Pubitemid 46606386)
3. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008;29: 217-233
4. Rose-Hellekant TA, Schroeder MD, Brockman JL, et al. Estrogen receptor-positive mammary tumorigenesis in TGFα transgenic mice progresses with progesterone receptor loss. Oncogene 2007;26: 5238-5246
5. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst 2005;97:1254-1261 (Pubitemid 41535366)
6. Howell A. The endocrine prevention of breast cancer. Best Pract Res Clin Endocrinol Metab 2008;22: 615-623
7. Jordan VC, Lababidi MK, Langan-Fahey S. Suppression of mouse mammary tumorigenesis by long-term tamoxifen therapy. J Natl Cancer Inst 1991;83:492-496
8. Medina D, Kittrell FS, Hill J, Shepard A, Thordarson G, Brown P. Tamoxifen inhibition of estrogen receptor-α-negative mouse mammary tumorigenesis. Cancer Res 2005;65:3493-3496 (Pubitemid 40524637)
9. Menard S, Aiello P, Tagliabue E, et al. Cancer Res 2000;60:273-275
10. Osborne MP, Ruperto JF, Crowe JP, Rosen PP, Telang NT. Effect of tamoxifen on preneoplastic cell proliferation in N-nitroso-N-methylurea-induced mammary carcinogenesis. Cancer Res 1992;52: 1477-1480
11. Ting AY, Kimler BF, Fabian CJ, Petroff BK. Tamoxifen prevents premalignant changes of breast, but not ovarian, cancer in rats at high risk for both diseases. Cancer Prev Res 2008;1:546-553
12. Rose-Hellekant TA, Gilchrist K, Sandgren EP. Strain background alters mammary gland lesion phenotype in transforming growth factor-α transgenic mice. Am J Pathol 2002;161:1439-1447
13. Rose-Hellekant TA, Wentworth KM, Nikolai S, Kundel DW, Sandgren EP. Mammary carcinogenesis is preceded by altered epithelial cell turnover in transforming growth factor-α and c-myc transgenic mice. Am J Pathol 2006;169:1821-1832 (Pubitemid 351182011)
14. Lakhani SR. The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 1999; 187:272-278 (Pubitemid 29064150)
15. Goldstein NS, Kestin U, Vicini FA. Monomorphe epithelial proliferations: characterization and evidence suggesting they are the pool of partially transformed lesions from which some invasive carcinomas arise. Am J Clin Pathol 2007;128: 1023-1034
16. O'Connell P, Pekkel V, Fuqua SA, Osborne CK, Clark GM, Allred DC. Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst 1998;90:697-703. (Pubitemid 28222144)
17. Xu S, Wei B, Zhang H, Qing M, Bu H. Evidence of chromosomal alterations in pure usual ductal hyperplasia as a breast carcinoma precursor. Oncol Rep 2008;19:1469-1475
18. Medina D, Kittrell FS, Shepard A, Contreras A, Rosen JM, Lydon J. Hormone dependence in premalignant mammary progression. Cancer Res 2003;63:1067-1072 (Pubitemid 36278440)
19. Nanni P, Nicoletti G, De Giovanni C, et al. Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12. Int J Cancer 2003; 105:384-389 (Pubitemid 36570052)
20. Telang NT, Bradlow HL, Osborne MP. Effect of tamoxifen on mammary preneoplasia: relevance to chemopreventive intervention. Cancer Detect Prev 1994;18:313-321
21. Yoshidome K, Shibata MA, Couldrey C, Korach KS, Green JE. Estrogen promotes mammary tumor development in C3(1)/SV40 large T-antigen transgenic mice: paradoxical loss of estrogen receptor α expression during tumor progression. Cancer Res 2000;60:6901-6910
22. Allred DC, Mohsin SK, Fuqua SA. Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 2001;8:47-61.
23. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90: 1371-1388 (Pubitemid 28439961)
24. Mohsin SK, Allred DC, Osborne CK, et al. Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer. Breast Cancer Res Treat 2005;94: 205-211
25. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333
26. Rohan TE, Negassa A, Chlebowski RT, et al. Estrogen plus progestin and risk of benign proliferative breast disease. Cancer Epidemiol Biomarkers Prev 2008;17:2337-2343
27. Wang DY, Fentiman IS. Epidemiology and endocrinology of benign breast disease. Breast Cancer Res Treat 1985;6:5-36. (Pubitemid 15241227)
28. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 2004;96:621-628 (Pubitemid 38584986)
29. Hoogerbrugge N, Bult P, de Widt-Levert LM, et al. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 2003;21:41-45
30. Maucort-Boulch D., Roy P. Modeling the effect of tamoxifen chemoprevention on long-term mortality in white women at high risk of breast cancer. Eur J Cancer Prev 2006;15:347-352 (Pubitemid 44060490)
31. Cardiff RD, Anver MR, Gusterson BA, et al. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000;19: 968-988